Recommended

Explore a smarter way to restore immune homeostasis in this upcoming webinar! Secure your place now!
Discover how lab automation is transforming early preclinical research in this upcoming webinar, register your details today!
Discover how artificial intelligence is transforming drug discovery in this innovative report! Download your very own copy now!
Solve the AOC puzzle in this expert-led webinar! Secure your place today to join the discussion!
article

Drug Target Review Antibodies ebook 2021

Posted: 31 March 2021 | | No comments yet

Within this ebook, find articles on how a lead bNAb candidate was identified to combat COVID-19 and why antibodies could present the answer to HIV treatment and vaccines. 

Antibodies are a vital part of therapeutic treatment as researchers continue to make significant developments in the biologics field, especially as monoclonal antibodies (mAbs) show great promise. 

Here, we discuss how a broadly neutralising antibody (bNAb) lead was created and selected with the potential to combat SARS-CoV-2 and results from two pre-clinical studies into how antibodies can be used as treatments and prophylactics for HIV. 

Included in this ebook:

  • Developing a broadly neutralising antibody therapeutic to combat SARS-CoV-2
    Dr Laura Walker, Adagio Therapeutics 
  • Fighting HIV: could antibodies be the answer?
    Victoria Rees, Drug Target Review 

    To read this in-depth focus in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Agilent

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Leave a Reply

    Your email address will not be published. Required fields are marked *